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ABSTRACT
Although they are considered as antigen-presenting cells, the role of
antigen-unspecific B lymphocytes in antigen presentation and T-lympho-
cyte stimulation remains controversial. In this paper, we tested the capac-
ity of normal human peripheral activated B cells to stimulate T cells using
melanoma antigens or melanoma cell lysates. B lymphocytes activated
through CD40 ligation and then pulsed with tumor antigens efficiently
processed and presented MHC class II-restricted peptides to specific
CD4 T-cell clones. This suggests that CD40-activated B cells have the
functional and molecular competence to present MHC class II epitopes
when pulsed with exogenous antigens, thereby making them a relevant
source of antigen-presenting cells to generate T cells. To test this hypoth-
esis, CD40-activated B cells were pulsed with a lysate prepared from
melanoma cells and used to stimulate peripheral autologous T cells.
Interestingly, T cells specific to melanoma antigens were generated. Ad-
ditional analysis of these T-cell clones revealed that they recognized MHC
class II-restricted epitopes from tyrosinase, a known melanoma tumor
antigen. The efficient antigen presentation by antigen-unspecific activated
B cells was correlated with a down-regulation in the expression of HLA-
DO, a B cell-specific protein known to interfere with HLA-DM function.
Because HLA-DM is important in MHC class II peptide loading, the
observed decrease in HLA-DO may partially explain the enhanced antigen
presentation after B-cell activation. Results globally suggest that when
they are properly activated, antigen-unspecific B-lymphocytes can present
exogenous antigens by MHC class II molecules and stimulate peripheral
antigen-specific T cells. Antigen presentation by activated B cells could be
exploited for immunotherapy by allowing the in vitro generation of T cells
specific against antigens expressed by tumors or viruses.
INTRODUCTION
B lymphocytes have the capacity to present exogenous proteins to
T cells after antigen-specific internalization by their surface immuno-
globulins. This MHC class II-restricted presentation is an important
step in the establishment of the humoral response (1, 2). In addition,
B cells can endocytose and present antigens in an immunoglobulin-
independent fashion. For example, EBV-transformed B cells have the
capacity to present tumor antigens by MHC class II (3, 4). In addition,
both DCs4 and B lymphocytes from spleen can present a peptide
derived from hen egg lysosyme by MHC class II after the injection of
the protein (5). However, the in vivo consequence of antigen process-
ing by unspecific B cells remains elusive, and there is conflicting
evidence whether these B cells interact with T cells in a tolerogenic or
immunogenic fashion (6–10).
Previous studies have shown that in some conditions, resting B cells
can be tolerogenic (7, 8, 10, 11). Activation signals may be required
to condition unspecific B lymphocytes to become competent APCs for
T-cell activation and antigen presentation. Stimulatory signals can be
provided to B cells from different sources, such as from activated T
cells expressing CD40L and secreting cytokines such as IL-4. CD40-
activation of B cells increases different aspects of APC function (7,
10, 11). Specifically, activation of a B-cell line by the CD40 receptor
increased MHC class II-restricted antigen presentation (12). The rea-
son for enhanced T-cell recognition of activated B cells is not clear,
but may be a function of altered expression of proteins involved in
MHC class II antigen processing and presentation.
Antigen presentation by the MHC class II pathway is dependent on
the involvement of several key proteins implicated in MHC class II
maturation and sorting, as well as proteins favoring the loading of
stable peptides. Among them, the invariant chain is known to asso-
ciate with the newly synthesized MHC class II molecules in the
endoplasmic reticulum to chaperone transport to the MIIC (13). In
MIICs, the invariant chain is degraded leaving a small fragment called
CLIP in the peptide binding site of the class II molecules (14). An
accessory molecule, HLA-DM, catalyzes the removal of the CLIP
fragment and peptides having low affinity to MHC molecules, which
promotes the loading of peptides with higher stability (15–17). Al-
though HLA-DM is expressed in all of the APCs, B lymphocytes also
express HLA-DO, another nonclassical MHC accessory molecule
(18). By interacting with HLA-DM (19) and possibly impairing its
function, HLA-DO modifies the peptide repertoire associated with
surface MHC class II molecules in favor of low affinity peptides (20,
21). Indeed, HLA-DO was postulated to indirectly favor presentation
of antigens taken up by the surface immunoglobulins by inhibiting
class II loading of nonspecific proteins in early compartments of the
endocytic pathway. Because HLA-DO changes the peptide/MHC
class II repertoire, its presence or absence could impact the B- and
T-lymphocyte interaction.
In this study, antigen-unspecific B lymphocytes from peripheral
blood lymphocytes of human donors were stimulated with CD40L and
IL-4 in a primary cell culture system, and analyzed for their ability to
present exogenous antigens by MHC class II. Data presented suggest
that such stimulation of B cells increased the presentation of exoge-
nous antigens by MHC class II molecules. Furthermore, B-cell acti-
vation provoked a consistent decrease in the expression of HLA-DO.
As a source of antigen, we used lysates from tumor cells, which are
known to contain a number of weakly immunogenic antigens, to
stringently test the immunogenicity of these B cells. Importantly,
CD40-activated B cells pulsed with melanoma lysates had the capac-
ity to generate antigen-specific CD4 T cells from resting PBMCs.
This data suggests that when properly activated, antigen-unspecific B
cells can be efficient APCs.
MATERIALS AND METHODS
Cell Culture. Immortalized EBV-B cells from patient 1088, and melanoma
cell lines 1088mel, 888mel, and 553mel were prepared as described previously
(4). The melanoma line SK23mel and the breast cancer line MDA231 were
obtained from the American Type Culture Collection (Manassas, VA). EBV-B
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cells and tumor lines were cultured in RPMI 1640 (Invitrogen, Gaithersburg,
MD) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen),
1 mM glutamine, 50 units/ml penicillin, 50 g/ml streptomycin (all from
Biofluids Inc., Rockville, MD), and 50 g/ml gentamicin (Invitrogen).
B lymphocytes and some of the T cells were cultured in complete medium
consisting of Iscove’s Modified Dulbecco’s medium (Invitrogen) supple-
mented with 10% human AB serum (male, heat inactivated; Gemini Bio-
Products, Calabasas, CA), 1 mM glutamine, 50 units/ml penicillin, 50 g/ml
streptomycin, and 50 g/ml gentamicin (all from Invitrogen).
To generate CD40-activated B-cell cultures, purified B cells (using a
negative selection system; StemCell Technologies Inc., Vancouver, British
Columbia, Canada) or bulk PBMCs were cultured with either 500 ng/ml of a
soluble trimeric CD40L (soluble trimeric CD40L; Immunex Corporation,
Seattle, WA). Cells were cultured in complete medium complemented with
200 units/ml of recombinant human IL-4 (Peprotech, Rocky Hill, NJ). When
using the StemCell enrichment system, we routinely obtained 95% B lym-
phocytes with no detectable T cells or monocytes. Fresh complete medium was
added again on day 3 with IL-4 (and 500 ng/ml soluble trimeric CD40L if
used). After the first round of proliferation (days 5–8), cells were either frozen
for future use or restimulated every 2–3 days when the culture reached a
density of 1.5–2  106 cells/ml. They were replated at about 3–5  105
cells/ml of medium (containing 500 ng/ml of CD40L) and 200 units/ml IL-4.
The anti-gp100 clone was prepared by limiting dilution of a bulk T-cell
culture after 2 stimulations with gp100-transduced CD34-derived DCs, and
were cultured and characterized as described previously (22).
Phenotypic Analysis and MLR. Fluorescence-activated cell sorter analy-
ses were performed using phycoerythrin- or FITC-labeled antibodies specific
to human CD3, CD14, CD19, CD20, CD21, CD40, CD80, CD86, and
HLA-DR (all from Becton-Dickinson, San Jose, CA), CD83 (Immunotech,
Marseille, France), or isotype-matched controls (Becton Dickinson). Labeled
cells were collected and analyzed using a FACScan cytofluorometer (Becton
Dickinson), and analysis was done with CellQuest software (Becton Dickin-
son). Propidium Iodine was used to exclude dead cells from analysis.
MLR was performed as described previously (22). Briefly, 1  105 allo-
geneic-enriched T cells (human T-cell immunoaffinity columns; R&D Inc.,
Minneapolis, MN) were cocultured with increasing numbers of irradiated
(1500 rads) PBMCs or CD40 and IL-4-activated B cells prepared from the
same donor in 96-well flat-bottomed tissue culture plates for 6 days. T-cell
proliferation was monitored by [3H]thymidine (DuPont New England Nuclear,
Boston, MA) incorporation for the last 16 h. Results were corrected for
[3H]thymidine incorporation by irradiated CD40-B cells and T cells alone.
Pulsing of CD40-activated B Cells and Recognition by CD4 T-Cell
Clones. Cell lysates were prepared by five successive freeze/thaw cycles of
1  107 cells/ml in Iscove’s based complete medium containing 10% human
AB serum. CD40-activated B cells were plated at 1 105 cells/well in 96-well
plates in 100 l or 1–2  106 cells/well in 24-well plates in 500 l in B-cell
medium without IL-4. Lysates were added for 16–20 h to reach a ratio of B
cell:lysed cell of 1:1 to 1:0.5 depending on the toxicity of the lysate on B-cell
viability as determined by trypan blue exclusion. For a recognition assay in
96-well plates, T cells were added for an additional 24 h. For a T-cell
stimulation assay, pulsed B cells from 24-well plates were harvested and
irradiated at 15 Gy.
In some experiments, chloroquine (Sigma, St. Louis, MO) was used at 100
M for 4 h before antigen pulsing on B cells. Cells were then washed and
cultured for 20 h in the presence of 5 M of chloroquine with or without gp100.
Cells were washed once and fixed with 0.5% of formaldehyde for 5 min. Cells
were then washed extensively three times and cocultured with T cells in a
96-well plate assay.
Western Blots. B lymphocytes were purified from PBMCs using a nega-
tive selection system (StemCell Technologies Inc.). B cells were 95% pure
based on flow cytometry analysis. Cells were left untreated or stimulated with
500 ng/ml of CD40L and 200 units/ml of IL-4 in B-cell culture medium for a
different period of time as indicated in “Results.” Protein extracts were
prepared as described previously (23). The amount of protein in each sample
was determined by the Bradford method to ensure even loading on the gels.
Samples were boiled for 5 min under nonreducing conditions in SDS loading
buffer and loaded on 10% SDS-PAGE. Proteins were transferred on nitrocel-
lulose membranes (Amersham Pharmacia Biotech, Buckinghamshire, Eng-
land) and saturated in tris buffer saline-tween 0.190 (TT135)-milk for 1 h as
recommended by the manufacturer. Antibodies were incubated overnight at
4°C. Polyclonal antibodies were first incubated for 1 h on a blank membrane
in TTBS-milk to remove background. After three washes in TTBS, a peroxi-
dase-coupled antibody was added for 1 h. After three more washes, the
peroxidase substrate [BM Chemiluminescence Blotting Substrate (POD);
Roche Diagnostics Corporation, Indianapolis, IN] was added, and the mem-
branes were exposed on Fuji Medical X-ray films (Fuji Photo Film CO., LDT,
Tokyo, Japan).
Membranes were washed using the ReBlot-Western blot recycling kit
(Chemicon International Inc., Temecula, CA) and reprobed using an actin-
specific antibody to ascertain equal loading of proteins. The films were
analyzed with Gel Pro Analyzer (1993–97; Media Cybernetics, Silver Spring,
MD). This software measures gray densities of protein spots found on a
scanned film. Values of stimulated cells were normalized compared with those
of actin. These normalized values were compared with gross values of non-
stimulated cells [Normalized value  (actin value of nontreated cells/actin
values of treated cells)  antigen presentation molecule values]. Ratios were
then calculated with relevant combinations of molecules to observe expression
differences after cell activation. Nonstimulated cell ratios were adjusted to 1,
and stimulated cell ratios were calculated accordingly so they could be com-
pared with the nonstimulated ratios.
Antibodies. DA6.147 is a monoclonal antibody (IgG1) directed against the
cytoplasmic tail of the HLA-DR chain (24). The rabbit antisera against the
cytoplasmic tails of HLA-DO or HLA-DM have been described previously
(25). Mouse antiactin is a monoclonal antibody that recognizes the NH2-
terminal two-thirds of the cellular actin molecules (Chemicon International,
Inc.). Secondary peroxidase-coupled antibodies are directed against the Fc part
of mouse immunoglobulins (used with primary monoclonal antibodies) or
heavy and light chain of rabbit immunoglobulins (used with primary poly-
clonal antibodies; Jackson ImmunoResearch Laboratories, Inc., Mississauga,
Ontario, Canada).
Stimulation of Autologous T Lymphocytes with Pulsed CD40-activated
B Cells. In the first T-cell generation experiment, the T-cell donor was a
melanoma patient from the Surgery Branch (National Cancer Institute) who
previously received two i.m. injections of Vaccinia-gp100 and one injection of
FowlPox-gp100 on Institutional Review Board-approved protocols. Irradiated
CD40-activated B cells (1  105) pulsed with a lysate prepared from the
melanoma line 1088mel were cocultured with 1  105 autologous PBMCs in
a 96-well plate in complete Iscove’s based medium containing 10% human AB
serum. Cell cultures were restimulated with 1  105 1088mel lysate-pulsed
CD40-activated B cells per well on day 11. IL-2 (Chiron, Emeryville, CA) was
added on day 13 and again every 3–4 days at 600 IU/ml. Individual wells were
assayed by coculture with 1  105 CD40-activated B cells pulsed with lysates
prepared from 1088mel or a control cell line MDA231. After 16–24 h,
GM-CSF secretion was evaluated by ELISA from culture supernatants using
coupled antibody pairs from (Endogen, Woburn, MA) using the protocol
provided by the manufacturer. Streptavidin-peroxidase (Research Diagnostic
Inc., Flanders, NJ) was added at a dilution of 1:4000 followed by peroxidase
substrate (Dako, Carpinteria, CA).
In the second T-cell generation study, the T-cell donor was a melanoma
patient from the Surgery Branch (National Cancer Institute), and cells were
obtained before any immunizations. Irradiated washed CD40-activated B cells
(2  105) pulsed with a lysate prepared from 1088mel were cocultured with
purified CD4 T cells (5  105; human T-cell immunoaffinity columns; R&D
Inc.) in complete Iscove’s base medium containing 10% human AB serum in
1 well of a 24-well plate. Cultures were restimulated with 1088mel lysate
CD40-activated B cells on day 11, and IL-2 was added on day 13 and again
every 3–4 days at 150 IU/ml. Cultures were restimulated again on day 17 using
1088mel lysate-pulsed B cells. Culture cells were cloned by limiting dilution
on day 28 as described previously (22, 26). Clones were cultured in complete
medium using AIM-V (Invitrogen) supplemented with 5% human AB serum,
1 mM glutamine, 50 units/ml penicillin, 50 g/ml streptomycin, 50 g/ml
gentamicin, and 300 IU/ml of IL-2.
All of the recognition assays were carried out in 96-well plates (flat-
bottomed) by coculture of 1  105 target cells and 1  105 responder T cells
for 20–24 h in 200–250 l. Supernatants were harvested, and IFN- or
GM-CSF were assayed by ELISA using coupled antibody pairs from Endogen.
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RESULTS
B-Cell Presentation of an Exogenous Antigen by MHC Class II.
B lymphocytes were first enriched from PBMCs prepared from nor-
mal donors. B-lymphocyte purity and phenotype were additionally
confirmed by flow cytometry analyses. After the negative selection
enrichment procedure, 95% of the cells expressed B-cell markers
such as CD19, CD20, and CD21 (Fig. 1A), which were additionally
confirmed by the absence of markers for T cells or monocytes (Fig.
1B). Before stimulation, purified B cells showed the following phe-
notype: CD19/CD20/CD21 (B-cell markers), CD3 (T-cell
markers), CD14 (monocyte/macrophage markers), HLA-DR,
CD40, CD80low, CD86low, and CD83 (APC markers). After
CD40L and IL-4 stimulation, the phenotype was CD19/CD20low/
CD21low (B cell markers), CD3 (T cell markers), CD14 (mono-
cyte/macrophage markers), HLA-DR, CD40low, CD80low, CD86,
and CD83 (APC markers). Importantly, CD40L/IL-4 stimulation
resulted in the generation of a highly homogeneous population of
CD19/CD20 B cells.
CD40L and IL-4-stimulated B lymphocytes were efficient in allo-
geneic T-cell stimulation in MLR as presented in Fig. 1D, consistent
with a previous report (27).
The capacity of activated human primary B cells to present an
exogenous tumor antigen by MHC class II molecules was then eval-
uated. B cells enriched from PBMCs were stimulated with CD40L and
IL-4 individually or in combination. At a variety of time points,
activated B cells were pulsed for 18–24 h with recombinant gp100, a
melanoma antigen. Class II-restricted presentation of gp100 was as-
sessed using a T-cell clone specific for an HLA-DR10701 gp100-
epitope (22). Purified B cells pulsed with antigen on day 0 that were
either nonstimulated (NS d0) or stimulated with IL-4 alone (IL-4 d0)
were weakly recognized by the gp100-specific CD4 T-cell clone
(Fig. 2A). However, the recognition was enhanced when gp100-pulsed
B cells were stimulated with CD40L alone (CD40L d0) or a combi-
nation of CD40L and IL-4 (CD40L/IL-4 d0). The recognition of B
cells cultured with CD40L and IL-4 for 5 days before gp100 antigen
exposure was better compared with any other condition. These obser-
vations suggest that short-term stimulation with CD40L is sufficient
to increase the capacity of B cells to present exogenous antigens by
MHC class II.
In a second experiment, purified B cells cultured with CD40L or a
combination of CD40L and IL-4, pulsed with gp100 antigen 2 days
later were efficiently recognized by gp100-specific CD4 T cells
(Fig. 2B; CD40L d2 and CD40L/IL-4 d2). The recognition was
specific to gp100 since CD40L/IL-4-stimulated B cells were not
recognized when pulsed with the control protein NY-ESO-1 (Fig. 2, A
and B), which is a recombinant protein prepared similarly to gp100.
Again, gp100-pulsed B cells that were unstimulated or cultured in
IL-4 alone were not efficiently recognized. Also, no recognition was
observed when HLA-DR10701 CD40-activated B cells were
pulsed with gp100 (Fig. 2B), confirming the specificity of the MHC
restriction element. B lymphocytes stimulated with either CD40L or
IL-4 alone were not cultured for 3 days because of lack of prolif-
eration.
Finally, to determine whether intracellular antigen processing was
required for presentation by MHC class II, CD40/IL-4-activated B
cells were first treated with chloroquine, which inhibits the processing
of exogenous antigen and presentation by MHC class II by neutral-
izing the pH of endosomes. As presented in Fig. 2C (left section),
chloroquine treatment resulted in inhibition of MHC class II presen-
tation of exogenous gp100, suggesting that intracellular processing
was required for MHC class II presentation. Importantly, this inhibi-
tion was not because of chloroquine toxicity because similar treat-
ments of tumor cell lines did not inhibit MHC class I-mediated
presentation of endogenous gp100 when using a CD8 T-cell clone
specific for an HLA-A0201 epitope.
These observations suggest that activation of human B cells with
CD40L enhances the capacity to present an exogenous tumor antigen
by MHC class II, and that intracellular antigen processing is required.
MHC class II-restricted presentation of exogenous antigens was ef-
fective in CD40-activated B cells cultured for 16 days (data not
shown). The reason for enhanced antigen presentation after B-cell
activation is not clear, but may involve a differential expression of
molecules involved in MHC class II antigen processing.
Fig. 1. Phenotypic analysis of B lymphocytes enriched from PBMCs. Expression of B
lymphocyte markers (A), T lymphocyte or monocyte/macrophage markers (B), and APC
markers (C) was assessed on PBMCs and purified B lymphocytes, before and after culture
with CD40L and IL-4, as described in “Materials and Methods.” Results are representative
of more than two independent experiments. B-cell purity after the enrichment procedure
was routinely evaluated. D, CD40/IL-4-activated B lymphocytes or PBMCs from the
same donor were irradiated and incubated with 1  105 allogeneic T cells at various cell
ratios as indicated. [3H]thymidine was added for the last 16 h of a 6-day proliferation
assay, and incorporation was measured as described in “Materials and Methods” (repre-
sentative of 15 similar experiments). White area represents fluorescence with isotype
matched control conjugated-antibodies; N/A, not available.
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Differential Expression of HLA-DR, -DM, and -DO Correlates
with Increased Antigen Presentation Activity. The above results
show that on activation, antigen-unspecific B cells can present soluble
antigens to T cells. This could be caused by multifactorial events such
as increased expression of costimulatory molecules, secretion of cy-
tokines, increase in endocytosis, or enhancement in antigen process-
ing and presentation. Interestingly, the group of Liljedahl (28) dem-
onstrated recently that HLA-DO expression in B cells inhibits the
presentation of such soluble fluid-phase endocytosed antigens.
HLA-DO is almost exclusively expressed in B lymphocytes and
interacts with HLA-DM to form a heterotetrameric structure (19). As
a consequence of its association with HLA-DM and the colocalization
in the MHC class II peptide loading compartment (MIIC), HLA-DO
modulates the MHC class II/peptide repertoire (20, 21, 29). We
reasoned that CD40 activation of B cells would probably lead to a
decrease in the expression of this nonclassical class II molecule in our
system. To investigate this potential mechanism in the observed
enhancement in antigen presentation after B-cell activation, we ana-
lyzed the expression of molecules known to be critical for MHC class
II antigen processing (15–17, 30). Analysis of HLA-DR, -DM, and
-DO expression was performed by Western blotting on total cell
extracts from control cells and B cells activated for various period of
time. Importantly, resting B cells highly expressed HLA-DO, which
probably contributes to their inability to efficiently present soluble
antigens to T cells. After activation with CD40L and IL-4, a contin-
uous decrease in the expression of HLA-DO was observed as early as
2 days after activation, with only a faint band visible 6 days after
activation (Fig. 3A). Additional analysis of the autoradiograms re-
vealed that the band intensity ratios for HLA-DR:DO and HLA-
DM:DO gradually increased after B-cell activation (Fig. 3B). The
ratios for nonstimulated cells were adjusted to 1 to facilitate the
analysis of the results. The HLA-DR/DO band intensity ratios in-
creased to 6 (donor A) and 4 (donor B) after 2 days of activation, and
additionally increased to 50 (day 13 for donor A) and 31 (day 16 for
donor B) at later time points. The HLA-DM:DO band intensity ratios
also increased to 9 (day 9 for donor A) and 10 (day 6 for donor B) but
at later time points compared with the HLA-DR:DO band intensity
ratios.
These data suggest that the enhanced recognition of pulsed-acti-
vated B cells by the specific CD4 T cells could be a consequence of
a change in the expression of molecules involved in antigenic pres-
entation by MHC class II, such as a decrease in HLA-DO expression.
Generation of Melanoma Antigen-specific T Cells Using CD40-
activated B Cells Pulsed with a Melanoma Lysate. Having dem-
onstrated that activated B cells can present exogenous antigens by
MHC class II and considering that they were efficient T-cell stimu-
lators (Fig. 1D), B cells were next evaluated for their capacity to
promote the generation of tumor-specific T cells from resting periph-
eral lymphocytes. As a source of antigen, we used lysates from tumor
cells, which are known to express a number of weakly immunogenic
self-antigens (31), thereby rigorously testing the stimulatory capacity
of the activated B cells.
Fig. 2. Presentation of gp100 by MHC class II by activated B cell. Purified B cells were concomitantly pulsed with recombinant gp100 protein and activated (d0) for 18–24 h (A)
or were preactivated for 2 days (d2) and pulsed with protein for an additional 18–24 h (B) as described in “Materials and Methods.” B cells preactivated with CD40L and IL-4 for
5, 7, or 9 days were subsequently pulsed with protein for 18–24 h as indicated (d5, d7, and d9, respectively). C, HLA-DR7 or -DR7 CD40L and IL-4-activated B cells (left section)
or tumor cells (right section) were treated with 100 M chloroquine (CHL) or were left untreated (NT). Cells were then washed, and B cells were pulsed with gp100 as indicated for
20 h in the presence of 5 M of chloroquine. Cells were washed once and fixed with 0.5% formaldehyde for 5 min. Cells were then washed extensively three times. For A–C, antigen
processing was assessed by coculturing the pulsed B cells with a CD4 T-cell clone specific to an MHC-DR10701-restricted epitope of gp100 (A–C, left section) or a CD8 T-cell
clone specific for an HLA-A0201 epitope of gp100 (C, right section) for an additional 18–24 h. Culture supernatants were collected and IFN- was measured using an ELISA assay
(pg/ml). ESO-1, NY-ESO-1 recombinant protein; gp100, gp100 recombinant protein; DR7, HLA-DR10701.
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CD40-activated B cells were pulsed with a lysate prepared from a
melanoma cell line and were used to stimulate autologous T cells from
blood. In experiment 1, PBMCs were stimulated in a 96-well plate
with autologous CD40-activated B cells pulsed with a lysate prepared
from the melanoma cell line 1088mel. After three stimulations with
1088mel lysate-pulsed B cells, all of the 96-wells were individually
tested against CD40-activated B cells pulsed with lysates prepared
from 1088mel or from the irrelevant breast cancer line MDA231.
Cells from 5 of the 96 wells were more reactive against the 1088mel
lysate-pulsed B cells (Fig. 4A) compared with those pulsed with the
MDA231 lysate. These results suggest that T cells reactive against
antigens expressed in 1088mel were generated.
In a second experiment, CD4 T cells purified from a different
donor were stimulated three times with 1088mel lysate-pulsed autol-
ogous CD40-activated B cells 10 days apart in 1 well of a 48-well
plate. The T-cell culture was cloned by limiting dilution and from 80
clones screened, 2 were consistently reactive against CD40-stimulated
B cells pulsed with 1088mel lysate but not against those pulsed with
a lysate prepared from MDA231 (Fig. 4B). The recognition was
specific for melanoma because both clones failed to recognize a lysate
prepared from EBV-immortalized B cells generated from patient
1088, excluding the possibility of recognition of allogeneic antigens.
Both T-cell clones were expanded using B cells pulsed with
1088mel lysate as stimulators. Clone 2 specifically expanded when
stimulated with autologous B cells pulsed with 1088mel lysate (Fig.
5A), but failed to proliferate when stimulated with autologous B cells
pulsed with a lysate from MDA231 or allogeneic B cells pulsed with
either lysates from 1088mel or MDA231. Additional characterization
of these two T-cell clones revealed that the antigen recognized was
shared by at least two other melanoma cell lines (SK23mel and
553mel) when lysates were pulsed on B cells (Fig. 5B). Also, the
recognition of CD40-activated B cells pulsed with 1088mel lysate was
inhibited using a blocking pan-MHC class II antibody or an anti-
HLA-DR antibody (data not shown), suggesting that the recognition
was HLA-DR restricted. HLA-restriction was additionally character-
ized using CD40-activated B cells from HLA-DR-matched donors
pulsed with 1088mel lysates. Clone 1 recognized only pulsed CD40-
activated B cells prepared from HLA-DR11501 donors (Fig. 5C).
In contrast to clone 1, clone 2 recognized only pulsed CD40-activated
B cells prepared from HLA-DR10401 donors, demonstrating that
recognition by clones 1 and 2 was, respectively, HLA-DR11501
and HLA-DR10401 restricted.
To determine the antigen recognized, lysates were prepared from
COS cells transfected with a panel of known melanoma tumor anti-
gens (4, 22, 32). By using these pulsed B cells as targets for clones 1
and 2, tyrosinase was identified to be the antigen recognized by both
clones (Fig. 5D). This observation was confirmed using B cells pulsed
with lysates prepared from COS cells infected with a fowlpox virus
vector expressing tyrosinase (data not shown).
In summary, T cells reactive against melanoma were generated
using CD40-activated B-lymphocytes pulsed with lysates prepared
from melanoma cells. These data suggest that CD40-activated B cells
are efficient APCs in the presentation of exogenous antigens by MHC
class II molecules and have the capacity to generate antigen-specific
T cells.
Finally, clone 2 was used to examine whether B-cell stimulationFig. 3. Differential expression of HLA-DR, -DM, and -DO in CD40-activated B
lymphocytes. Purified B cells were cultured in vitro in the absence (nonstimulated for 2
days; NS) or presence of 500 ng/ml of soluble trimeric CD40L and 200 units/ml of IL-4
for the indicated periods of time. A, extracts were prepared and analyzed by Western blots
using antibodies specific to the indicated molecules. Representative blots done on 2
donors are presented. B, the band intensities from the autoradiograms were evaluated and
the relative ratios for HLA-DR compared with -DO (DR/DO) and HLA-DM compared
with -DO (DM/DO) were calculated.
Fig. 4. Generation of 1088mel-specific T lymphocytes using CD40-activated B cells
pulsed with a tumor lysate. CD40-activated B cells were pulsed for 18–24 h with a lysate
prepared from the melanoma line 1088mel. A, autologous PBMCs were stimulated three
times with irradiated pulsed CD40-activated B cells as described in the “Materials and
Methods.” Single wells were assayed using B cells pulsed with lysates prepared from
1088mel or MDA231. Two representative negative cultures are shown on the left side. B,
purified CD4 T cells were stimulated three times with irradiated pulsed autologous
CD40-activated B cells, and cloning was done by limiting dilution as described in
“Materials and Methods.” Two clones were consistently reactive against CD40-stimulated
B cells pulsed with a lysate prepared from 1088mel and failed to secrete GM-CSF when
incubated with B cells pulsed with lysates prepared from MDA231 or EBV-B cells from
donor 1088. For A and B, T cells and targets were cocultured for 20–24 h, supernatants
were collected and GM-CSF secretion was evaluated by ELISA (pg/ml).
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was required for the presentation of the HLA-DR10401-restricted
tyrosinase epitope. Purified B cells were left unstimulated or were
activated by CD40L, IL-4, or a combination of these. B cells were
then pulsed with lysates from 1088mel and used to stimulate clone 2.
Clone 2 was reactive against B cells pulsed with antigen on day 0 and
stimulated with CD40L alone (Fig. 6A; CD40L d0) or a combination
of CD40L and IL-4 (CD40L/IL-4 d0), but failed to recognize B cells
that were either nonstimulated (NS d0) or stimulated with IL-4 alone
(IL-4 d0). The recognition of B cells cultured with CD40L and IL-4
for 5 days before antigen exposure was better compared with any
other condition. These observations confirmed that short-term stimu-
lation with CD40L is sufficient to increase the capacity of B cells to
present exogenous antigens by MHC class II, as presented previously
in Fig. 2A. Similarly, purified B cells cultured with CD40L or a
combination of CD40L and IL-4, pulsed with 1088mel lysate 2 days
later were efficiently recognized by clone 2 (Fig. 6B; CD40L d2 and
CD40L/IL-4 d2). The recognition was specific to tyrosinase, because
CD40L/IL-4-stimulated B cells were not recognized when pulsed with
control lysate prepared from 1088-EBV-B cells (Fig. 6, A and B),
which do not express tyrosinase.
These data additionally validate the original observation suggesting
that activation of human B cells with CD40L enhances the capacity to
present an exogenous tumor antigen by MHC class II.
DISCUSSION
In the present work, we studied the consequences of CD40-activa-
tion on antigen presentation and T-cell stimulatory capacity of normal
human antigen-unspecific B lymphocytes. Results presented show
that CD40-activation of B cells increased their ability to present
exogenous antigens by MHC class II. Indeed, B lymphocytes have
critical functions of antigen uptake, processing, and presentation in
the context of the humoral response, where antigens are taken up by
the rare B cells expressing antigen-specific surface immunoglobulins,
a situation that has been extensively studied. In the present paper, we
show that after CD40-activation, nontransformed normal human B
lymphocytes can uptake, process, and present exogenous antigens
independent of the surface immunoglobulins. Interestingly, this ex-
perimental system allows the culture of primary B cells for up to 3
weeks, and a direct correlation was found between the length of
activation and their ability to stimulate T cells. These CD40-activated
B cells pulsed with a lysate prepared from melanoma cells had the
capacity to generate T cells specific to melanoma. Our data suggest
that indeed, when properly activated, B cells can present exogenous
antigens by MHC class II molecules and stimulate antigen-specific T
cells.
B-cell activation modulates the activity of other processes involved
in antigen presentation such as increase in fluid-phase endocytosis,
increase in the expression of costimulatory molecules (as shown in
Fig. 1C demonstrating increased CD86 expression; Refs. 9, 33), and
secretion of immunomodulatory cytokines (34). It is possible that
activation of B cells by CD40L results in a number of changes leading
to enhanced antigen presentation and T-cell stimulatory capacity. In
this study, MHC class II antigen presentation by B cells correlated
with the differential expression of classical and nonclassical MHC
Fig. 5. T-cell clones generated by stimulation with melanoma lysate-pulsed activated B cells recognized tyrosinase epitopes presented by HLA-DR10401 and HLA-DR11501.
A, proliferation of clone 2 (1  105 on day 0) after stimulation with autologous or HLA-DR-unmatched (allogeneic) CD40-activated B cells pulsed with 1088mel or MDA231 lysates.
Viable cells were counted on the basis of trypan blue exclusion using a hemacytometer. B–D, clones 1 and 2 were cocultured for 18–24 h with (B) autologous CD40-activated B cells
pulsed with lysates prepared from 1088-EBV-B cells or from different tumor lines as indicated (MDA 231 is a breast cancer line, all others are melanoma lines), (C) CD40-stimulated
B cells prepared from HLA-DR matched donors pulsed with lysates prepared from 1088-EBV-B cells or 1088mel, and (D) autologous CD40-activated B cells pulsed with lysates
prepared from 1088-EBV-B cells, 1088mel, or COS cells expressing green fluorescent protein or tyrosinase. Supernatants were collected and GM-CSF (B and D) or IFN- (C) were
assayed by ELISA (pg/ml). auto CD40-B, autologous CD40-activated B cells; allo CD40-B, allogeneic CD40-activated B cells.
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class II molecules after activation by CD40L. The expression of
HLA-DO, a molecule described previously to alter the MHC class
II/peptide repertoire and to inhibit the presentation of nonspecific
exogenous soluble antigens, was decreased after B-cell activation with
CD40L. By using B cells stimulated with an antibody specific to IgM
compared with unstimulated cells, Roucard et al. (35) have reported a
50% decrease in the expression of HLA-DO, but no functional anal-
ysis of antigen processing was performed. In contrast to our work, no
decrease in HLA-DO expression was observed when stimulating B
cells with IL-4 and an antibody against CD40. Perhaps the decrease in
HLA-DO that we observed after activation was because of B-cell
stimulation with the more physiological soluble trimeric form of
CD40L compared with the use of an antibody against the receptor. An
increase in the HLA-DR:DO and HLA-DM:DO ratios should allow
the loading of a broader repertoire of peptides, which bind with more
stability to surface HLA molecules. Additionally, antigen-unspecific
B cells that become activated by T cells may also increase their
capacity to load antigens in less acidic compartments because of the
diminished expression of HLA-DO. The down-regulation of HLA-DO
might be one of several events leading to improved APC functions in
addition to other mechanisms enumerated earlier. The exact mecha-
nisms by which DO is down-regulated and potentially influences
antigen presentation are currently under investigation.
The results presented suggest that, after CD40-activation, antigen-
unspecific normal human B cells can efficiently present exogenous
antigens through MHC class II. CD40L is mainly expressed on
activated CD4 T cells (36). In vivo, unspecific B lymphocytes could
receive CD40 stimulation from activated CD4 T cells during an
immune response. We hypothesize that antigen-unspecific B cells
receive stimulatory signals from activated CD4 T cells, and as a
consequence, B cells present exogenous antigens to T cells. The
involvement of antigen-unspecific B cells in T-cell activation could
enhance the magnitude of the T-cell response in an immune reaction.
Although we used weakly immunogenic tumor cells as a source of
antigen, B cells may also play a role in presenting more immunogenic
foreign antigens after viral or bacterial infections. Additional work is
needed to define the relevance of T-cell activation by antigen-unspe-
cific B cells in vivo.
CD40-activated B cells can present exogenous antigens by MHC
class II, and they are effective in the generation of antigen-specific T
cells. For in vitro use, B cells have a number of advantages compared
with other APCs, such as DCs, including a high proliferation rate,
which allows the generation of a many activated B cells, even from
cryopreserved PBMCs. This would allow the generation of an effec-
tive source of APCs when a small amount of blood is available (27).
Antigen-specific T cells generated from lysate-pulsed activated B
cells could be used to identify new tumor antigens from common
cancers for vaccine development. In addition, tumor antigen-pulsed
CD40-activated B cells could be used to generate specific T cells for
adoptive immunotherapy, which has been demonstrated recently to
result in high response rates in melanoma patients (37).
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